Trials / Completed
CompletedNCT01627054
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- NCIC Clinical Trials Group · Network
- Sex
- All
- Age
- 18 Months
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out what effects a new drug AT7519M has on chronic lymphocytic leukemia.
Detailed description
This research is being done because AT7519M has been shown to shrink tumours in animals, has been studied in a few people and seems promising, but it is not clear if it can offer better results than standard treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AT7519M | Dose: 27 mg/m2, IV injection, 1 hour infusion Schedule: 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11) |
Timeline
- Start date
- 2012-08-27
- Primary completion
- 2014-03-21
- Completion
- 2015-02-13
- First posted
- 2012-06-25
- Last updated
- 2023-08-04
Locations
3 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT01627054. Inclusion in this directory is not an endorsement.